Non-dilutive growth lines for cash-pay virtual clinics, underwritten on prescription refill cohorts instead of equity.

1. Large institutional capital is already entering this niche through Customer Value Fund structures rather than waiting for equity rounds.
2. Cash-pay compounded care categories create repeat purchase behavior that can be modeled at the cohort level instead of treated like one-time ecommerce revenue.
3. The use of proceeds is explicitly customer acquisition, which creates a clear buyer, budget, and ROI loop for a wedge product.
4. Revenue-share financing is emerging as the preferred structure for this segment, leaving room for a purpose-built underwriting and monitoring layer.

Catalyst. Musely's non-dilutive CVF financing proves that scaled consumer-health acquisition is now credible collateral for institutional capital.

Telehealth Cohort Capital plugs into a clinic's ad accounts, patient acquisition funnel, prescribing workflow, pharmacy fulfillment, and repayment data to score each growth cohort before funding it. The first product is a non-dilutive acquisition line that advances budget for specific campaigns and gets repaid through a capped share of collected cohort revenue. The software continuously monitors refill persistence, refund rates, and compliance signals, then automatically adjusts draw limits as performance changes. That gives capital partners a live underwriting dashboard and gives clinics faster, cheaper funding than equity or generic revenue-based financing. Over time, the company becomes the system of record for how cash-pay care cohorts are priced.

What's different. Generic revenue-based financing providers look at trailing revenue and bank statements. This product underwrites the actual engine that repays the advance, namely prescription acquisition cohorts, refill persistence, and category-specific compliance data. That creates better pricing for strong operators and a proprietary dataset that gets more valuable as more clinics and capital providers join the network.

Jobs to be done

flowchart LR
  Buyer[CFO at virtual clinic] --> Pain[Needs CAC budget without dilution]
  Pain --> Product[Cohort underwriting plus revenue-share line]
  Product --> Outcome[Scales paid acquisition with tracked payback]

Executive takeaways

• Musely's $360M Customer Value Fund facility is direct evidence that institutional capital will finance virtual-clinic patient acquisition without taking equity when recurring cohorts are strong enough [1].
• Scaled cash-pay telehealth can support very large acquisition budgets: Hims & Hers reported $2.35B of 2025 revenue and $919.3M of marketing expense, with 2.511M subscribers and $83 monthly revenue per average subscriber [2][3].
• The best beachhead is narrower than “telehealth”: recurring, cash-pay derm/hair/menopause clinics where refill cadence, collected revenue, and channel attribution are observable enough to underwrite [1][3][9][10][11][12][13][14].
• Generic financiers already validate demand for non-dilutive growth capital, but Capchase, Wayflyer, Clearco, and Pipe publicly position around SaaS, ecommerce, or platform transaction data rather than prescription persistence and compliance [17][18][19][20].
• Demand-side signals are real—Rock Health says U.S. digital health funding rebounded to $14.2B in 2025 and virtual care remains mainstream—but acquisition constraints are tightening through ad-policy, health-claims, and personalized-care oversight [5][6][8][21][22][23].
• This is partner-meeting-worthy only if the founders can secure privileged data access across ads, prescribing, fulfillment, and collections; otherwise the product collapses into another generic revenue-based financing tool [1][3][20].

Market definition

This market is not telehealth broadly; it is U.S. non-dilutive growth capital for cash-pay virtual clinics that buy patients online into recurring prescription or membership programs, especially dermatology, hair-loss, and menopause care. The buyer is the clinic finance/growth leader, and the asset being financed is cohort-level collected revenue from recurring care—not insurance receivables, generic SMB working capital, or traditional venture debt [1][3][9][10][11][12][13][14][17][18][19][20].

Customer and buyer

ICP: U.S. CFOs, CEOs, and VPs of Growth at virtual clinics with $10M-$100M revenue, meaningful paid acquisition, and repeat prescription or membership revenue. Economic buyer is usually the CFO/CEO; the day-to-day user is finance/growth ops. End-patient cash willingness is visible in public offers: Evernow advertises menopause care starting at $35/month and $150 self-pay visits, Midi lists $250 initial and $150 follow-up self-pay visits, and Ro sells recurring plans starting at $48/month, which makes cohort-level collected revenue legible enough to finance [9][10][11][12][13][14].

Buying triggers

• Paid channels are working, but the clinic wants to scale acquisition without selling equity; Musely explicitly used a non-dilutive facility to supercharge customer acquisition. [1]
• Recurring subscriber economics become predictable enough to finance when cohorts show repeat collections; Hims reported 2.511M subscribers and $83 monthly revenue per average subscriber in 2025. [3]
• Menopause and women’s-health demand can justify dedicated budget because untreated symptoms create measurable employer and healthcare costs; Midi cites a $24.8B annual burden from insufficient menopause symptom management. [12]

Willingness to pay

Patient-side willingness to pay is already visible in recurring cash-pay offers: Evernow advertises menopause memberships starting at $35/month and $150 self-pay visits; Midi lists $250 initial and $150 continued-care visits for self-pay patients; Ro publishes recurring medication plans starting at $48/month. That does not prove clinic willingness to pay for capital, but it does show the underlying revenue stream is cash-collected and subscription-like [9][10][13][14]. [9][10][13][14]

Category dynamics

Growth signal 17.9% CAGR (teledermatology market, 2025-2030 cross-check)

Validation signals

• Musely secured more than $360M in non-dilutive capital from GC’s Customer Value Fund to finance customer acquisition.
• Hims & Hers generated $2.35B of 2025 revenue, spent $919.3M on marketing, and ended the year with roughly 2.511M subscribers, proving scaled cash-pay telehealth economics exist.
• Rock Health says U.S. digital health funding reached $14.2B in 2025, up 35% from 2024.
• Evernow says it is trusted by 160,000+ women and offers both membership and per-visit menopause care.
• Midi markets menopause care as insurance-covered and pitches employers on a quantified $24.8B burden from insufficient symptom management.
• Generic funding providers already market CAC financing, ecommerce growth funding, and multi-draw capital products, confirming broader appetite for non-dilutive growth finance.

Regulatory & technical constraints

• Changes to rules or enforcement around personalized offerings, compounding, and telehealth sales/marketing could abruptly impair clinic demand or repayment.
• Google treats online pharmacies and telemedicine providers as regulated prescription-drug-service advertisers, requiring compliance and limiting ad terms.
• Personalized advertising has targeting restrictions for sensitive categories, which can degrade paid-acquisition efficiency for health offers.
• FTC requires health claims to be supported by competent and reliable evidence, constraining creative and messaging for funded campaigns.
• Underwriting requires reliable integrations across ad, clinical, fulfillment, and collections systems; without clean telemetry, the risk model is weak.

Incumbents split between bespoke institutional capital and generic growth financiers. General Catalyst can supply large, customized facilities to breakout brands, but that is not the same as a productized underwriting OS for mid-market clinics [1][24][25]. Capchase, Wayflyer, Clearco, and Pipe all validate demand for non-dilutive growth funding, yet their public materials focus on SaaS contracts, ecommerce inventory/cash flow, or embedded-finance transaction data rather than prescription refills, pharmacy fulfillment, and telehealth compliance [17][18][19][20]. Vertical clinics like Ro, Evernow, and Midi are better viewed as target customers or substitutes for self-funding than as neutral financing platforms [9][10][11][12][13][14].

Why incumbents do not win by default

• Institutional bespoke capital. General Catalyst-style vehicles do not win by default because they appear optimized for very large, proven operators; the startup’s wedge is productizing cohort underwriting and monitoring for smaller clinics that are too operationally messy for bespoke deals.
• Generic revenue-based financers. Capchase, Wayflyer, Clearco, and Pipe already finance growth, but their public underwriting narratives center on SaaS contracts, ecommerce sales, or platform payments data—not prescription persistence, refill cadence, clinical refunds, or claims/compliance risk.
• Vertical clinic operators. Ro, Evernow, and Midi are operating companies selling care, not neutral capital infrastructure. They can internalize financing decisions for their own funnels, but that does not automatically translate into third-party underwriting services for competing clinics.
• Ad platforms and cloud tools. Google controls traffic policy, but not collections, refill behavior, or loss outcomes; policy restrictions actually increase the value of a specialist lender that can reprice exposure by channel and indication.
• In-house spreadsheets. Public comparator data from Hims shows how many variables matter—subscriber growth, marketing mix, monthly revenue per subscriber, and personalized treatment mix—so smaller clinics are unlikely to match institutional underwriting discipline with ad hoc finance models.

Telehealth Cohort Capital is a non-dilutive growth-finance platform for U.S. cash-pay virtual clinics that acquire patients online into recurring prescription programs. The beachhead is virtual dermatology, hair-loss, and menopause clinics with $10M-$100M in annualized revenue, meaningful Meta/Google spend, and refill behavior that can be observed at the cohort level. The product combines read-only data integrations, cohort underwriting, and capped revenue-share facilities so a clinic CFO can scale a working channel without raising equity or flattening spend to internal cash flow. Research supports the customer pain and timing: Musely's $360M Customer Value Fund facility shows institutional appetite for financing virtual-clinic acquisition, while Hims-scale marketing spend and subscriber data show that large recurring cash-pay cohorts exist. The company's advantage is not cheaper money alone but better underwriting on prescription persistence, collections, refunds, and compliance-adjusted channel performance. The first proof point is a pilot with one scaled clinic and one capital partner that demonstrates verified cohort telemetry can support faster redraws and acceptable loss behavior. The biggest disconfirming risk is that target clinics will not share direct access to ad, prescribing, pharmacy, and collections systems, in which case the product collapses into generic revenue-based financing. Market size estimates are based on research assumptions rather than audited industry counts, so the company should treat TAM, SAM, and SOM as testable planning ranges, not facts.

Problem

• Cash-pay virtual clinics with strong payback still choose between founder dilution, generic revenue-based financing priced on trailing revenue, or throttling acquisition to internal cash flow.
• Traditional lenders and generic financiers do not underwrite refill persistence, pharmacy fulfillment, refunds, or telehealth compliance risk, so strong operators are priced like weak ones.

Solution

• Offer a cohort-specific acquisition line that plugs into ad accounts, prescribing workflow, pharmacy fulfillment, and collections data, then advances capital against verified recurring-care cohorts.
• Monitor refill persistence, collected revenue, refund rates, and policy/compliance signals continuously so draw limits and pricing can be adjusted before losses compound.

Why we win

• The wedge underwrites the repayment engine itself—prescription cohorts and collected revenue—rather than broad historical revenue, which should produce better selection and pricing for the best operators.
• Proprietary cross-clinic benchmarks on channel CAC, refill persistence, and compliance-adjusted repayment can compound into a dataset generic RBF players do not have.

Milestones

flowchart LR
  Wedge[Derm or menopause clinic CFO with a working paid channel] --> MVP[Read-only integrations plus manual cohort underwriting]
  MVP --> Proof[First pilot facility with verified redraw and loss data]
  Proof --> Expansion[More clinic stacks, more capital partners, broader specialty coverage]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least 5 of the first 10 serious target clinics will grant read-only access to ad, prescribing, pharmacy, and collections systems during diligence.
• Historical cohort data from at least 3 clinics will show refill and collection behavior predictive enough to price a 1.2x-1.5x capped repayment product.
• One external capital partner will fund a pilot facility without requiring the startup to carry the full balance sheet.
• Clinics will prefer cohort-priced acquisition capital over generic RBF or delayed equity at the proposed fee and repayment structure.
• Compliance or ad-policy changes will be manageable through repricing and tranche controls rather than causing broad facility freezes.

Open diligence questions

• Which clinic systems and pharmacy partners are present in the first two pilots, and how long does each integration take?
• What do 12-month cohort curves show for CAC, refill decay, refunds, and collected revenue by indication and channel?
• Who absorbs first-loss risk in the pilot structure: the startup, the capital partner, or the clinic through pricing and holdbacks?
• How concentrated is early repayment exposure in therapies or marketing claims facing compounding or telehealth scrutiny?
• What advantage will stop Capchase, Pipe, or a bespoke fund from copying the workflow once the asset class is legible?

Model sanity

• Revenue engine. Base-case revenue comes from growing from one pilot clinic in Y1 to five active facilities by Q4Y2 and six by Q4Y3 while revenue per clinic rises with redraw utilization.
• Must go right. The company must win data-room access and capital-partner approval on time because the sales-cycle sensitivity shows roughly a $330K cash hit if closings slip by one quarter.
• Model breaks if. The downside case goes cash-negative if data-ready clinic conversion slows and gross margin compresses to 68% from extra servicing burden.
• Next-round proof. The seed-ready proof point is reaching at least five active clinics plus a second capital partner and automated redraw reporting by month 24.

Scenarios

Sensitivity

flowchart LR
  TargetAccounts --> Diligence
  Diligence --> ActiveClinics
  ActiveClinics --> FundedVolume
  FundedVolume --> Revenue
  Revenue --> GrossProfit
  GrossProfit --> Cash

Flags: Base case assumes asset-light economics and excludes credit losses, reserve requirements, or warehouse interest if the company later puts capital on balance sheet. · Revenue concentration is high because five clinics drive all Y2 revenue and six clinics drive all Y3 revenue. · External capital-partner timing and clinic data-sharing are still pre-validation assumptions, so a one-quarter slip pushes the model materially closer to a cash crunch.

• Regulatory shock. Changes to compounded-telehealth rules could suddenly reduce demand or impair repayment across funded clinics. Mitigation: Start with diversified exposure across dermatology, hair, and menopause operators and embed compliance gating into underwriting.
• Channel volatility. A Meta or Google algorithm change can quickly break cohort payback assumptions. Mitigation: Monitor cohorts daily, cap exposure by channel, and release capital in tranches tied to performance.
• Adverse selection. The clinics most eager for non-dilutive capital may be the ones with weakening retention or poor data quality. Mitigation: Require direct system integrations, begin with small pilot limits, and price only on verified collections and refill behavior.